Beltrán Hernandez Briam, Fernández-Sarmiento Jaime, Mulett Hernando, Niño Ariza Maria Carolina, Aguirre Gutierrez Valeria, Cárdenas Carolina, Cardona María Paula, Bernal Sierra Tatiana, Cabezas Rosas Marisol, Garzón Angel Lina, Sarta Mauricio, Fernández-Sarta Juan Pablo, La Rotta Isabella, Buelvas-Pérez Juanita, Rodriguez Laura Sofia, Barrera Suárez Maria José, Kissoon Niranjan
Department of Pediatrics and Intensive Care, Fundación Cardioinfantil-Instituto de Cardiología, Bogotá, Colombia.
School of Medicine and Health Sciences. Universidad del Rosario, Bogotá, Colombia.
Pediatr Crit Care Med. 2025 Aug 1;26(8):e1024-e1033. doi: 10.1097/PCC.0000000000003782. Epub 2025 Jun 25.
To evaluate the association between hyperprocalcitonemia and endothelial and microcirculatory dysfunction in children with sepsis and septic shock and clinical outcomes.
A prospective observational cohort study, 2021-2024.
A tertiary PICU with 15 medical-surgical beds in a university hospital.
We included children with sepsis and/or septic shock who had serum procalcitonin measured at admission, 24 hours, and 48 hours, simultaneously with microcirculatory assessment using sublingual videomicroscopy and biomarkers of endothelial injury (syndecan-1, angiopoietin-2, and endocan). Hyperprocalcitonemia was defined as procalcitonin greater than 2 ng/mL.
None.
In 230 patients, 43.9% (101/230) had hyperprocalcitonemia at PICU admission. After adjusting for confounders, children with hyperprocalcitonemia, compared with those with normal procalcitonin, had higher adjusted odds ratio (aOR [95% CI]) of reduced capillary blood flow at 24 hours (aOR, 1.35 [95% CI, 1.08-1.72]) and 48 hours (aOR, 1.14 [95% CI, 1.04-1.24]) after admission. At 24 hours, children with hyperprocalcitonemia compared with those without hyperprocalcitonemia had higher median (interquartile range [IQR]) syndecan-1 levels (125.87 ng/mL [IQR, 49.56-224.30 ng/mL] vs. 107.71 ng/mL [IQR, 62.82-156.55 ng/mL], respectively; p < 0.01) and greater odds of angiopoietin-2 elevation (aOR, 2.28 [95% CI, 1.08-5.17]; p = 0.042). Hyperprocalcitonemia with severe endothelial/microcirculatory dysfunction was associated with fluid overload greater than 10% (aOR, 2.01 [95% CI, 1.06-3.80]; p = 0.033), multiple organ dysfunction (aOR, 1.87 [95% CI, 1.01-3.57]; p = 0.041), and mortality (aOR, 1.66 [95% CI, 1.06-2.61]; p = 0.022). We failed to identify differences in capillary density (4-6 µm), angiopoietin-2, or Endocan between children with and without hyperprocalcitonemia at PICU admission.
Children with sepsis and septic shock with hyperprocalcitonemia represent a phenotype characterized by endothelial and microvascular dysfunction, which is associated with worse clinical outcomes. Our study suggests that preserving microvascular integrity may be a therapeutic target to reduce microcirculatory damage and improve outcomes.
评估脓毒症和脓毒性休克患儿血清降钙素原水平升高与内皮及微循环功能障碍之间的关联及其临床结局。
一项前瞻性观察队列研究,时间跨度为2021年至2024年。
一所大学医院中设有15张内科-外科床位的三级儿科重症监护病房。
纳入在入院时、24小时及48小时均检测血清降钙素原的脓毒症和/或脓毒性休克患儿,同时采用舌下视频显微镜评估微循环,并检测内皮损伤生物标志物(多配体蛋白聚糖-1、血管生成素-2和内皮糖蛋白)。血清降钙素原水平升高定义为降钙素原大于2 ng/mL。
无。
230例患者中,43.9%(101/230)在儿科重症监护病房入院时血清降钙素原水平升高。校正混杂因素后,血清降钙素原水平升高的患儿与降钙素原水平正常的患儿相比,入院后24小时(校正比值比[aOR][95%置信区间]为1.35[95%CI,1.08 - 1.72])和48小时(aOR为1.14[95%CI,1.04 - 1.24])时毛细血管血流减少的校正比值比更高。在24小时时,血清降钙素原水平升高的患儿与未升高的患儿相比,多配体蛋白聚糖-1水平的中位数(四分位间距[IQR])更高(分别为125.87 ng/mL[IQR,49.56 - 224.30 ng/mL]和107.71 ng/mL[IQR,62.82 - 156.55 ng/mL];p < 0.01),血管生成素-2升高的几率更大(aOR为2.28[95%CI,1.08 - 5.17];p = 0.042)。伴有严重内皮/微循环功能障碍的血清降钙素原水平升高与液体超负荷超过10%(aOR为2.01[95%CI,1.06 - 3.80];p = 0.033)、多器官功能障碍(aOR为1.87[95%CI,1.01 - 3.57];p = 0.041)及死亡率(aOR为1.66[95%CI,1.06 - 2.61];p = 0.022)相关。我们未能发现儿科重症监护病房入院时血清降钙素原水平升高与未升高的患儿在毛细血管密度(4 - 6 µm)、血管生成素-2或内皮糖蛋白方面存在差异。
脓毒症和脓毒性休克且血清降钙素原水平升高的患儿具有以内皮和微血管功能障碍为特征的表型,这与更差的临床结局相关。我们的研究表明,维持微血管完整性可能是减少微循环损伤并改善结局的治疗靶点。